Enovis ( (ENOV) ) has provided an announcement.
On February 25, 2025, Enovis Corporation announced that its CEO, Matthew L. Trerotola, plans to retire once a successor is appointed. To ensure a smooth transition, Trerotola will serve as an Executive Advisor for one year following the appointment of the new CEO. The company is actively searching for a growth-oriented leader in the MedTech industry to continue its focus on innovation and patient outcomes. This leadership change comes as Enovis positions itself for continued growth and industry leadership.
More about Enovis
Enovis Corporation is an innovation-driven medical technology company focused on developing clinically differentiated solutions that improve patient outcomes and transform workflows. The company offers a wide range of products, services, and integrated technologies, primarily in the field of orthopedics, and is listed on the New York Stock Exchange under the symbol ENOV.
YTD Price Performance: -1.74%
Average Trading Volume: 796,418
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: $2.48B
See more data about ENOV stock on TipRanks’ Stock Analysis page.